TNF Pharmaceuticals, Inc. Common Stock (TNFA)

• Market cap: $1.32M
• 1 day: -2.62%
• 5 days: -11.16%
• 1 month: -59.41%
• 3 months: -64.78%
• 6 months: -73.24%
• Year to date: -58.35%
• 1 year: -85.57%
• 5 years: -99.64%
• 10 years: -99.64%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

Employees: 6

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

142% more capital invested

Capital invested by funds: $60.3K [Q3] → $146K (+$85.6K) [Q4]

20% more funds holding

Funds holding: 20 [Q3] → 24 (+4) [Q4]

3.02% more ownership

Funds ownership: 1.57% [Q3] → 4.6% (+3.02%) [Q4]